As CEO Jeff Missling prepares for a great week of partnering events at JPM 2025, we are proud to officially launch frenellepharma.com, a portfolio of companies leveraging our proprietary long-acting injectable technology. Connect with Jeff via BIO 1:1 Partnering. https://lnkd.in/gHG77S8A
关于我们
SpineThera designs and develops sustained-release, injectable drugs to meet the unique safety requirements for administration in and near the spine. Our proprietary drugs offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs.
- 网站
-
https://www.SpineThera.com
SpineThera的外部链接
- 所属行业
- 制药业
- 规模
- 2-10 人
- 总部
- Minneapolis
- 类型
- 私人持股
- 创立
- 2012
地点
-
主要
获取路线
US，Minneapolis
SpineThera员工
动态
-
SpineThera Celebrates Milestone Achievement with 7th Patent Issued by the US Patent and Trademark Office https://lnkd.in/grDhg5Fa
-
SpineThera to Collaborate With Mayo Clinic to Advance Solutions in Substance Abuse Disorder Treatment https://lnkd.in/gf_XWf3Y
-
ProMed Pharma Acquires SpineThera Manufacturing Capabilities and an Option to License Intellectual Property The sale of its manufacturing operation is consistent with SpineThera’s drug-product asset-development focus. SpineThera’s Chief Executive Officer, Jeff Missling, remarked, “We are focused on improving patients lives by developing innovative injectable drugs based on our proprietary micro-suspension platform technology. Our lead asset, SX600, has shown best-in-class potential for the treatment of lumbar radicular pain. Importantly, SpineThera is maintaining exclusive ownership of intellectual property that enables SX600. With this transaction, our manufacturing team joins a highly capable CDMO, ProMed Pharma, a company we have worked with closely for many years. SpineThera becomes a customer of ProMed, who will manufacture SX600 in the same cleanroom in which we previously developed the technology and manufactured clinical batches. This transaction provides an infusion of working capital and reduces our fixed and recurring expenses.” Missling added, “I thank our employees who have made the transition to ProMed for their years of dedicated service at SpineThera. We look forward to continuing to partner to advance the development of SX600 so that patients suffering from severe lumbar radicular pain may have greatly improved pain management.” https://lnkd.in/gdDRuh7V